Plant Summary
Plant Information
TCMBank_ID: | TCMBANKHE004000 |
ID: | TCMBANKHE004000 |
植物拉丁名: |
|
功能与主治: | To dispel wind and remove obstruction from the channels and to remove heat from blood and cause subsidence of swelling./Wind-damp impediment pain, hypertonicity of sinews and vessels, aching in lumbus and knees, throat impediment, swollen welling abscess, knocks and falls. |
药用植物名: | 络石藤 |
药用部位: | leafy stem |
药味: | Minor cold; Bitter |
经络: | Liver; Heart |
临床特征: | 1. An active component arcitiin is a vasodilator and hypotensive. 2. Over dosage of arctiin may lead to convulsion and respiratory failure. |
治疗类型: | 祛风湿清热药 |
TCM_ID_id: | 4021 |
SymMap_id: | 261 |
TCMSP_id: | 485 |
植物对应的化合物
| 化合物ID | 化合物名 | 别名 | 分子式 | 分子质量 | Smiles |
|---|
| TCMBANKIN000962 | campesterol | campesterol ; FT-0082089; Augelicincampesterol; (24R)-5-Ergosten-3; (1R,3AS,3BR,9AS,9BS,11AR)-1-[(2R,5R)-5,6-DIMETHYLHEPTAN-2-YL]-9A,11A-DIMETHYL-1H,2H,3H,3AH,3BH,4H,5H,5AH,6H,9H,9BH,10H,11H-CYCLOPENTA[A]PHENANTHREN-7-OL; A-ol; 24(R)-Ergost-5-en-3beta-ol; 24alpha-Methyl-5-cholesten-3beta-ol; AK307302; SC-66911; (8R,9S,10S,13R,14S,17R)-17-((2R,5R)-5,6-Dimethylheptan-2-yl)-10,13-dimethyl-4,5,6,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-3-ol; AKOS027320474; MFCD00010475; Campesterin; MolPort-035-882-175 | C28H48O | 400.68 | CC(C)C(C)CCC(C)C1CCC2C1(CCC3C2CC=C4C3(CCC(C4)O)C)C |
| TCMBANKIN004208 | nortracheloside | C26H32O12 | 536.5 g/mol | COC1=C(C=CC(=C1)CC2COC(=O)C2(CC3=CC(=C(C=C3)OC4C(C(C(C(O4)CO)O)O)O)OC)O)O | |
| TCMBANKIN005138 | isoamaranthin | C30H34N2O19 | 726.6 g/mol | C1C(N=C(C=C1C=CN2C(CC3=CC(=C(C=C32)O)OC4C(C(C(C(O4)CO)O)O)OC5C(C(C(C(O5)C(=O)O)O)O)O)C(=O)O)C(=O)O)C(=O)O | |
| TCMBANKIN008174 | gomphrenin ii | C24H26N2O13 | C1C(NC(=CC1=CC=[N+]2C(CC3=CC(=C(C=C32)OC4C(C(C(C(O4)CO)O)O)O)O)C(=O)[O-])C(=O)O)C(=O)O | ||
| TCMBANKIN009098 | luteolin-4'-O-β-D-glucoside | C21H20O11 | 448.38 | ||
| TCMBANKIN010543 | arcitiin | ||||
| TCMBANKIN010781 | gomphreninI | gomphrenin i; gomphreninII; Gomphrenin I | C24H26N2O13 | 550.47 | C1C(N=C(C=C1C=CN2C(CC3=CC(=C(C=C32)OC4C(C(C(C(O4)CO)O)O)O)O)C(=O)O)C(=O)O)C(=O)O |
| TCMBANKIN012176 | amaranthin | C30H34N2O19 | 726.59 | C1C(NC(=CC1=CC=[N+]2C(CC3=CC(=C(C=C32)O)OC4C(C(C(C(O4)CO)O)O)OC5C(C(C(C(O5)C(=O)O)O)O)O)C(=O)[O-])C(=O)O)C(=O)O | |
| TCMBANKIN015073 | gomphrenin Ⅱ | ||||
| TCMBANKIN022571 | gomphrenin V | (2S)-1-[(2E)-2-[(2R)-2,6-dicarboxy-2,3-dihydro-1H-pyridin-4-ylidene]ethylidene]-5-hydroxy-6-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-[[(E)-3-(4-hydroxy-3-methoxyphenyl)prop-2-enoyl]oxymethyl]oxan-2-yl]oxy-2,3-dihydroindol-1-ium-2-carboxylate; AC1O3DEA; gomphrenin v | C34H34N2O16 | 726.6 g/mol | COC1=C(C=CC(=C1)C=CC(=O)OCC2C(C(C(C(O2)OC3=C(C=C4CC([N+](=CC=C5CC(NC(=C5)C(=O)O)C(=O)O)C4=C3)C(=O)[O-])O)O)O)O)O |
| TCMBANKIN023050 | TRE | (2R,3S,4S,5R,6R)-2-(hydroxymethyl)-6-[(2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydropyran-2-yl]oxy-tetrahydropyran-3,4,5-triol; EINECS 202-739-6; Treha; (2R,3S,4S,5R,6R)-2-methylol-6-[(2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-methylol-tetrahydropyran-2-yl]oxy-tetrahydropyran-3,4,5-triol; D-Trehalose; ZINC04095531; Trehalose (8CI); alpha-trehalose; Trehaose; alpha,alpha'-Trehalose; ST5409604; GLC-(1-1)GLC; C01083; alpha,alpha'-D-Trehalose; (2R,3S,4S,5R,6R)-2-(hydroxymethyl)-6-[[(2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)-2-tetrahydropyranyl]oxy]tetrahydropyran-3,4,5-triol; SMP1_000299; alpha-D-Glucopyranoside, a-D-glucopyranosyl (9CI); CHEBI:16551; (2R,3S,4S,5R,6R)-2-(hydroxymethyl)-6-[(2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-oxane-3,4,5-triol; 229966-89-6; (2R,3S,4S,5R,6R)-2-(hydroxymethyl)-6-[(2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxane-3,4,5-triol; NSC 2093; alpha-D-Glucopyranoside, alpha-D-glucopyranosyl; D(+)Trehalose; alpha-D-glucopyranosyl alpha-D-glucopyranoside; alpha-D-Glcp-(1<->1)-alpha-D-Glcp; alpha-D-Trehalose | C12H22O11 | 342.3 | C(C1C(C(C(C(O1)OC2C(C(C(C(O2)CO)O)O)O)O)O)O)O.O.O |
| TCMBANKIN023639 | Ibogain | DEA No. 7260; Ibogaine (8CI); NIH 10567; EINECS 201-498-4; 7-Ethyl-6,6beta,7,8,9,10,12,13-octahydro-2-methoxy-6,9-methano-5H-pyrido(1',2':1,2)azepino(5,4-b)indole; Tabernanthe iboga; 12-Methoxyibogamine; NSC 249764; 17378-46-0; Endabuse | C20H26N2O | 310.43 | CCC1CC2CC3C1N(C2)CCC4=C3NC5=C4C=C(C=C5)OC |
| TCMBANKIN025911 | gomphrenin vi | C34H34N2O16 | |||
| TCMBANKIN027838 | Lupeol acetate | lupeol acetate; 3-Acetyllupeol; Acetic acid (1R,3aR,4S,5aR,5bR,7aR,9S,11aR,11bR,13aR,13bR)-1-isopropenyl-3a,5a,5b,8,8,11a-hexamethyl-eicosahydro-cyclopenta[a]chrysen-9-yl ester; C08630; AIDS-076591; Lup-20(29)-en-3-ol, acetate, (3beta)-; LMPR01060014; AIDS076591; Lup-20(29)-en-3beta-ol, acetate (8CI); NSC 281806; 1617-68-1; EINECS 216-575-8 | C32H52O2 | 468.75 | CC(=C)C1CCC2(C1C3CCC4C5(CCC(C(C5CCC4(C3(CC2)C)C)(C)C)OC(=O)C)C)C |
| TCMBANKIN030171 | O-Acetyl-beta-amyrin | 3-O-Acetyl-beta-amyrin; acetic acid [(3S,4aR,6aR,6bS,8aR,12aR,14aR,14bR)-4,4,6a,6b,8a,11,11,14b-octamethyl-1,2,3,4a,5,6,7,8,9,10,12,12a,14,14a-tetradecahydropicen-3-yl] ester; [(3S,4aR,6aR,6bS,8aR,12aR,14aR,14bR)-4,4,6a,6b,8a,11,11,14b-octamethyl-1,2,3,4a,5,6,7,8,9,10,12,12a,14,14a-tetradecahydropicen-3-yl] ethanoate; beta-Amyrenyl acetate; NSC 403166; [(3S,4aR,6aR,6bS,8aR,12aR,14aR,14bR)-4,4,6a,6b,8a,11,11,14b-octamethyl-1,2,3,4a,5,6,7,8,9,10,12,12a,14,14a-tetradecahydropicen-3-yl] acetate; Olean-12-en-3-ol, acetate, (3beta)- (9CI); Olean-12-en-3beta-ol, acetate (8CI) | C32H52O2 | 468.75 | CC(=O)OC1CCC2(C(C1(C)C)CCC3(C2CC=C4C3(CCC5(C4CC(CC5)(C)C)C)C)C)C |
| TCMBANKIN030311 | ginsenoside rb0 | ||||
| TCMBANKIN033301 | gomioffithine | ||||
| TCMBANKIN033448 | isoamericanin a | (alphaE,2R)-2alpha-(3,4-Dihydroxyphenyl)-3beta-(hydroxymethyl)-2,3-dihydro-1,4-benzodioxin-6-propenal; 2alpha-(Hydroxymethyl)-3beta-(3,4-dihydroxyphenyl)-2,3-dihydro-1,4-benzodioxin 7-acrylaldehyde | C18H16O6 | 328.3 g/mol | C1=CC2=C(C=C1C=CC=O)OC(C(O2)C3=CC(=C(C=C3)O)O)CO |
| TCMBANKIN035363 | 5-METHYLTETRALIN | 2809-64-5; Naphthalene, 1,2,3,4-tetrahydro-5-methyl-; InChI=1/C11H14/c1-9-5-4-7-10-6-2-3-8-11(9)10/h4-5,7H,2-3,6,8H2,1H; 5-methyl-1,2,3,4-tetrahydronaphthalene | C11H14 | 146.23 | CC1=C2CCCCC2=CC=C1 |
| TCMBANKIN036873 | Ginsenoside Rd | ginsenoside-rd; ginsenosiderd; A829210; 2-(hydroxymethyl)-6-[6-(hydroxymethyl)-2-[[17-[2-[6-(hydroxymethyl)-3,4,5-tris(oxidanyl)oxan-2-yl]oxy-6-methyl-hept-5-en-2-yl]-4,4,8,10,14-pentamethyl-3,12-bis(oxidanyl)-2,3,5,6,7,9,11,12,13,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-6-yl]oxy]-4,5-b; 2-[[2-[[3,12-dihydroxy-4,4,8,10,14-pentamethyl-17-[6-methyl-2-[[3,4,5-trihydroxy-6-(hydroxymethyl)-2-oxanyl]oxy]hept-5-en-2-yl]-2,3,5,6,7,9,11,12,13,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-6-yl]oxy]-4,5-dihydroxy-6-(hydroxymethyl)-3-oxanyl]oxy]-6 | 947 | ||
| TCMBANKIN036917 | apigenin | 520-36-5; Spectrum2_000428; 10798_FLUKA; Biochem Biophys Res Comm 212: 767 (1997); CCRIS 3789; AIDS001401; apigenin-7-olate; KBioGR_002565; KBio3_002887; BSPBio_000368; 5,7-dihydroxy-2-(4-hydroxyphenyl)chromen-4-one; HSCI1_000221; Flavone, 4',5,7-trihydroxy-; 4H-1-Benzopyran-4-one, 5,7-dihydroxy-2-(4-hydroxyphenyl)-; EINECS 208-292-3; A3145_SIGMA; 7-hydroxy-2-(4-hydroxyphenyl)-4-oxo-1-benzopyran-5-olate; CHEBI:18388; IDI1_000798; NCGC00025057-04; AIDS-001401; NSC 83244; BPBio1_000406; Apigenol; 5,7-dihydroxy-2-(4-hydroxyphenyl)-4-chromenone; NINDS_000798; NCGC00015049-02; 4′,5,7-Trihydroxyflavone; SPBio_002307; Prestwick_719; 2-(4-hydroxyphenyl)-7-oxidanyl-4-oxidanylidene-chromen-5-olate; Spectrum4_001999; Chamomile; KBio1_000798; BRN 0262620; Prestwick2_000414; Prestwick3_000414; SDCCGMLS-0066379.P001; CHEBI:58470; 5,7, 4'-trihydroxyflavone; NCGC00025057-02; 2-(p-Hydroxyphenyl)-5,7-dihydroxychromone; 5,7-dihydroxy-2-(4-hydroxyphenyl)-4H-1-benzopyran-4-one; APIGENIN; Lopac0_000065; K00045; 4′,5,7-Trihydroxyflavone; 5,7-Dihydroxy-2-(4-hydroxyphenyl)-4-benzopyrone; NCGC00025057-09; 5,7-dihydroxy-2-(4-hydroxyphenyl)-4H-chromen-4-one; ACon1_002450; Oprea1_622293; EU-0100065; nchembio790-comp26; 4',5,7-Trihydroxyflavone; NCGC00025057-08; ND-9076; NCGC00025057-01; MEGxp0_000176; Apigenin; 4',5,7-Trihydroxyflavone; apigenin ; Prestwick1_000414; NCGC00015049-01; ZINC00004495; NCGC00025057-05; Spectrum3_001882; BiomolKI_000078; NCI60_041830; Bio1_001354; ghl.PD_Mitscher_leg0.1194; SPECTRUM200846; A828903; DivK1c_000798; 5-18-04-00574 (Beilstein Handbook Reference); 5-hydroxy-2-(4-hydroxyphenyl)-4-oxo-4H-chromen-7-olate; C.I. Natural Yellow 1; 461015-54-3; 4H-1-Benzopyran-4-one, 5,7-dihydroxy-2-(4-hydroxyphenyl)- (9CI); 5,7-dihydroxy-2-(4-hydroxyphenyl)chromone; SMP2_000338; BiomolKI2_000082; Prestwick0_000414; Tocris-1227; Lopac-A-3145; Bio1_000865; NSC83244; Versulin; Pelargidenon 1449; Bio1_000376; Spigenin; 5,7,4'-Trihydroxyflavone; ST056301; UCCF 031; SPBio_000416; Apigenine; C01477; CAS-520-36-5; BSPBio_003384 | C15H10O5 | 270.24 | C1=CC(=CC=C1C2=CC(=O)C3=C(C=C(C=C3O2)O)O)O |
| TCMBANKIN037939 | trachelogenin amide | COC1=C(C=C(C=C1)CC(CO)C(CC2=CC(=C(C=C2)O)OC)(C(=O)N)O)OC | |||
| TCMBANKIN038003 | Luteolin-4'-O-glucoside | 448.4 g/mol | |||
| TCMBANKIN038754 | Arctiin | 4-[(3,4-dimethoxyphenyl)methyl]-3-[(4-hydroxy-3-methoxyphenyl)methyl]-2-oxolanone; 2-(hydroxymethyl)-6-methyloxane-3,4,5-triol; (3R,4R)-4-[(3,4-dimethoxyphenyl)methyl]-3-[[3-methoxy-4-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydropyran-2-yl]oxy-phenyl]methyl]tetrahydrofuran-2-one; AIDS-002468; (3R,4R)-4-[(3,4-dimethoxyphenyl)methyl]-3-[[3-methoxy-4-[[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)-2-tetrahydropyranyl]oxy]phenyl]methyl]-2-tetrahydrofuranone; (3R,4R)-4-[(3,4-dimethoxyphenyl)methyl]-3-[[3-methoxy-4-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-phenyl]methyl]oxolan-2-one; 2(3H)-Furanone, 4-((3,4-dimethoxyphenyl)methyl)-3-((4-(beta-D-glucopyranosyloxy)-3-methoxyphenyl)methyl)dihydro-, (3R-trans)- (9CI); Arctiin (8CI); 2(3H)-Furanone, 4-[(3,4-dimethoxyphenyl)methyl]-3-[[4-(b-D-glucopyranosyloxy)-3-methoxyphenyl]methyl]dihydro-, (3R,4R)-; (3R,4R)-4-[(3,4-dimethoxyphenyl)methyl]-3-[[3-methoxy-4-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyphenyl]methyl]oxolan-2-one; AIDS002468; (3R,4R)-4-(3,4-dimethoxybenzyl)-3-[3-methoxy-4-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-methylol-tetrahydropyran-2-yl]oxy-benzyl]tetrahydrofuran-2-one; NSC 315527; ACon1_001261; 4-[(3,4-dimethoxyphenyl)methyl]-3-[(3-methoxy-4-oxidanyl-phenyl)methyl]oxolan-2-one; 2-(hydroxymethyl)-6-methyl-oxane-3,4,5-triol; MEGxp0_000527; A814488 | C27H34O11 | 535 | c1(OC([H])([H])[H])c([H])c(C([H])([H])[C@@]2([H])C(=O)OC([H])([H])[C@]2([H])C([H])([H])c3c([H])c(OC([H])([H])[H])c(O[C@]4([H])O[C@]([H])(C([H])([H])O[H])[C@@]([H])(O[H])[C@]([H])(O[H])[C@@]4([H])O[H]) c([H])c3[H])c([H])c([H])c1OC([H])([H])[H] |
| TCMBANKIN040211 | Ginsenoside Rg1 | ginsenosiderg1; ginsenoside r g1; sanchinoside C1; (20S)-3beta,12beta-Dihydroxy-4,4,8beta,14alpha-tetramethyl-6alpha,20-bis(beta-D-glucopyranosyloxy)-18-norcholestane-24-ene | 801.01 | ||
| TCMBANKIN040348 | Matairesinoside | (3R,4R)-4-[(4-hydroxy-3-methoxyphenyl)methyl]-3-[[3-methoxy-4-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyphenyl]methyl]oxolan-2-one; 23202-85-9; (3R,4R)-4-[(4-hydroxy-3-methoxy-phenyl)methyl]-3-[[3-methoxy-4-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-phenyl]methyl]oxolan-2-one; (3R,4R)-4-[(4-hydroxy-3-methoxyphenyl)methyl]-3-[[3-methoxy-4-[[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)-2-tetrahydropyranyl]oxy]phenyl]methyl]-2-tetrahydrofuranone; AIDS109046; AIDS-109046; (3R,4R)-4-(4-hydroxy-3-methoxy-benzyl)-3-[3-methoxy-4-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-methylol-tetrahydropyran-2-yl]oxy-benzyl]tetrahydrofuran-2-one; 2(3H)-Furanone, 3-[[4-(b-D-glucopyranosyloxy)-3-methoxyphenyl]methyl]dihydro-4-[(4-hydroxy-3-methoxyphenyl)methyl]-, (3R,4R)-; 2(3H)-Furanone, 3-((4-(b-D-glucopyranosyloxy)-3-methoxyphenyl)methyl)dihydro-4-((4-hydroxy-3-methoxyphenyl)methyl)-, (3R,4R)-; (3R,4R)-4-[(4-hydroxy-3-methoxy-phenyl)methyl]-3-[[3-methoxy-4-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydropyran-2-yl]oxy-phenyl]methyl]tetrahydrofuran-2-one; matairesinoside; STYRAXLIGNOLIDE E; CHEMBL520065 | C26H32O11 | 520.53 | COC1=C(C=CC(=C1)CC2COC(=O)C2CC3=CC(=C(C=C3)OC4C(C(C(C(O4)CO)O)O)O)OC)O |
| TCMBANKIN040444 | ginsenoside rc | 2-[[2-[[17-[2-[[6-[[3,4-dihydroxy-5-(hydroxymethyl)-2-oxolanyl]oxymethyl]-3,4,5-trihydroxy-2-oxanyl]oxy]-6-methylhept-5-en-2-yl]-12-hydroxy-4,4,10,14-tetramethyl-1,2,3,5,6,7,8,9,11,12,13,15,16,17-tetradecahydrocyclopenta[a]phenanthren-3-yl]oxy]-4,5-dihydr; ginsenosiderc; I06-0733; 2-(hydroxymethyl)-6-[6-(hydroxymethyl)-2-[[17-[2-[6-[[5-(hydroxymethyl)-3,4-bis(oxidanyl)oxolan-2-yl]oxymethyl]-3,4,5-tris(oxidanyl)oxan-2-yl]oxy-6-methyl-hept-5-en-2-yl]-4,4,10,14-tetramethyl-12-oxidanyl-1,2,3,5,6,7,8,9,11,12,13,15,16,17-tetradecahydrocy; A802167 | C53H90O22 | 1079.27 | CC(=CCCC(C)(C1CCC2(C1C(CC3C2CCC4C3(CCC(C4(C)C)OC5C(C(C(C(O5)CO)O)O)OC6C(C(C(C(O6)CO)O)O)O)C)O)C)OC7C(C(C(C(O7)COC8C(C(C(O8)CO)O)O)O)O)O)C |
| TCMBANKIN040725 | voacangine | voacangine ; SCHEMBL17340578 | C22H28N2O3 | 368.47 | CCC1CC2CC3(C1N(C2)CCC4=C3NC5=C4C=C(C=C5)OC)C(=O)OC |
| TCMBANKIN041204 | Vobasine | CHEMBL1628271; Vobasine; BDBM50378856 | 352.4 g/mol | ||
| TCMBANKIN042015 | trachelogenin 4'-o-β-gentiobioside | COC1=C(C=C(C=C1)CC2COC(=O)C2(CC3=CC(=C(C=C3)OC4C(C(C(C(O4)COC5C(C(C(C(O5)CO)O)O)O)O)O)O)OC)O)OC | |||
| TCMBANKIN042229 | nortrachelogenin-8'-o-β-d-glucopyranoside | ||||
| TCMBANKIN042397 | Dammara-20,24-dien-3beta-ol | dammara-20,24-dien-3β-ol; dammara-20,24-dien-3beta-ol | C30H50O | 468.75 | [C@@]1([H])(O[H])C([H])([H])C([H])([H])[C@](C([H])([H])[H])([C@@]([H])(C([H])([H])C([H])([H])[C@]([H])([C@]([H])(C(C([H])([H])C([H])([H])\C([H])=C(/C([H])([H])[H])\C([H])([H])[H])=C([H])[H])C([H])([H] )C2([H])[H])[C@@]23C([H])([H])[H])[C@@]3(C([H])([H])[H])C([H])([H])C4([H])[H])[C@]4([H])C1(C([H])([H])[H])C([H])([H])[H] |
| TCMBANKIN042858 | Luteolin | Prestwick3_000870; TNP00073; 2-(3,4-dihydroxyphenyl)-5-hydroxy-4-oxo-4H-chromen-7-olate luteolin-7-olate(1-); 62696_FLUKA; ACon1_000223; 2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-4-chromenone; Digitoflavone; SMR000326896; luteolin-7-olate anion; 4H-Benzopyran-4-one, 2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-; CHEBI:57545; FLAVONE, 3',4',5,7-TETRAHYDROXY-; 2-(3,4-Dihydroxyphenyl)-5,7-dihydroxy-4-benzopyrone; A827664; BPBio1_001011; MEGxp0_000143; 4H-1-Benzopyran-4-one, 2-(3,4-dihydroxyphenyl)-5,7-dihydroxy- (9CI); Weld Lake; BSPBio_000919; CHEBI:15864; 2-(3,4-dihydroxyphenyl)-5-hydroxy-4-oxo-4H-chromen-7-olate; 2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-chromen-4-one; Oprea1_849964; Yama kariyasu; 4-[5,7-bis(oxidanyl)-4-oxidanylidene-chromen-2-yl]-2-oxidanyl-phenolate; ST024703; luteolin ; NCGC00016467-02; EINECS 207-741-0; AIDS001406; NCGC00142375-02; C.I. Natural Yellow 2; S00110; Luteoline; Luteolin; Luteolol; 3′,4′,5,7-Tetrahydroxyflavone; 2-(3,4-dihydroxyphenyl)-5,7-dihydroxychromen-4-one; 4H-1-Benzopyran-4-one, 2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-; Prestwick_122; 5,7,3',4'-Tetrahydroxyflavone; BRN 0292084; CAS-491-70-3; 4-(5,7-dihydroxy-4-oxo-1-benzopyran-2-yl)-2-hydroxyphenolate; ZINC00008613; NCGC00142375-01; Prestwick1_000870; AIDS-001406; C01514; CCRIS 3790; 3',4',5,7-Tetrahydroxyflavone; Flacitran; Cyanidenon 1470; MLS000697655; SPBio_002840; 2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-4H-chromen-4-one; Lopac0_000660; NCGC00016467-01; C.I. 75590; Prestwick0_000870; 491-70-3; 2-(3,4-Dihydroxyphenyl)-5-hydroxy-7-oxylato-4H-1-benzopyran-4-one; 5-18-05-00296 (Beilstein Handbook Reference); Prestwick2_000870; 2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-4H-1-benzopyran-4-one; L9283_SIGMA; 3′,4′,5,7-Tetrahydroxyflavone; SMP2_000042; 2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-chromone | C15H10O6 | 286.236 | c1(O[H])c([H])c(OC(c2c([H])c([H])c(O[H])c(O[H])c2[H])=C([H])C3=O)c3c(O[H])c1[H] |
| TCMBANKIN042887 | gomphrenin iii | (2S)-1-[(2E)-2-[(2S)-2,6-dicarboxy-2,3-dihydro-1H-pyridin-4-ylidene]ethylidene]-5-hydroxy-6-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-[[(Z)-3-(4-hydroxyphenyl)prop-2-enoyl]oxymethyl]oxan-2-yl]oxy-2,3-dihydroindol-1-ium-2-carboxylate; AC1O3DE4 | C34H34N2O16 | 726.6 g/mol | COC1=C(C=CC(=C1)C=CC(=O)OCC2C(C(C(C(O2)OC3=C(C=C4CC(N(C4=C3)C=CC5=CC(=NC(C5)C(=O)O)C(=O)O)C(=O)O)O)O)O)O)O |
| TCMBANKIN044669 | Ibogaine | 310.4 g/mol | |||
| TCMBANKIN048063 | luteolin-7-o-gentiobioside | C27H30O16 | 610.5 g/mol | C1=CC(=C(C=C1C2=CC(=O)C3=C(C=C(C=C3O2)OC4C(C(C(C(O4)COC5C(C(C(C(O5)CO)O)O)O)O)O)O)O)O)O | |
| TCMBANKIN048153 | 5-hydroxy-2,8,6-trimethyl-8-(3,7-dimethyl-2,6-octadienyl)-2h-1-betzopyran-4,7(3h,8h)-dione | C22H30O4 | |||
| TCMBANKIN048381 | 2-heptanol | 189056-EP2380568A1 | C7H16O | 116.2 g/mol | CCCCCC(C)O |
| TCMBANKIN048584 | Apigenin-7-O-gentiobioside | 594.5 g/mol | |||
| TCMBANKIN048809 | nortrachelogenin-5'-c-β-d-glucopyranoside | ||||
| TCMBANKIN049389 | Gompyrenin III | C34H35N2O14 | c1(O[H])c([H])c2c(N(=C([H])\C([H])=C(/C([H])=C(C(=O)O[H])N([H])[C@]3([H])C(=O)C([H])([H])[H])\C3([H])[H])[C@]([H])(C(=O)O)C2([H])[H])c([H])c1O[C@]4([H])[C@]([H])(O[H])[C@@]([H])(O[H])[C@]([H])(O[H])[C @]([H])(C([H])([H])OC(=O)\C([H])=C([H])/c5c([H])c([H])c(O[H])c([H])c5[H])O4 | ||
| TCMBANKIN058221 | apigenin | 520-36-5; Spectrum2_000428; 10798_FLUKA; Biochem Biophys Res Comm 212: 767 (1997); CCRIS 3789; AIDS001401; apigenin-7-olate; KBioGR_002565; KBio3_002887; BSPBio_000368; 5,7-dihydroxy-2-(4-hydroxyphenyl)chromen-4-one; HSCI1_000221; Flavone, 4',5,7-trihydroxy-; 4H-1-Benzopyran-4-one, 5,7-dihydroxy-2-(4-hydroxyphenyl)-; EINECS 208-292-3; A3145_SIGMA; 7-hydroxy-2-(4-hydroxyphenyl)-4-oxo-1-benzopyran-5-olate; CHEBI:18388; IDI1_000798; NCGC00025057-04; AIDS-001401; NSC 83244; BPBio1_000406; Apigenol; 5,7-dihydroxy-2-(4-hydroxyphenyl)-4-chromenone; NINDS_000798; NCGC00015049-02; 4′,5,7-Trihydroxyflavone; SPBio_002307; Prestwick_719; 2-(4-hydroxyphenyl)-7-oxidanyl-4-oxidanylidene-chromen-5-olate; Spectrum4_001999; Chamomile; KBio1_000798; BRN 0262620; Prestwick2_000414; Prestwick3_000414; SDCCGMLS-0066379.P001; CHEBI:58470; 5,7, 4'-trihydroxyflavone; NCGC00025057-02; 2-(p-Hydroxyphenyl)-5,7-dihydroxychromone; 5,7-dihydroxy-2-(4-hydroxyphenyl)-4H-1-benzopyran-4-one; APIGENIN; Lopac0_000065; K00045; 4′,5,7-Trihydroxyflavone; 5,7-Dihydroxy-2-(4-hydroxyphenyl)-4-benzopyrone; NCGC00025057-09; 5,7-dihydroxy-2-(4-hydroxyphenyl)-4H-chromen-4-one; ACon1_002450; Oprea1_622293; EU-0100065; nchembio790-comp26; 4',5,7-Trihydroxyflavone; NCGC00025057-08; ND-9076; NCGC00025057-01; MEGxp0_000176; Apigenin; 4',5,7-Trihydroxyflavone; apigenin ; Prestwick1_000414; NCGC00015049-01; ZINC00004495; NCGC00025057-05; Spectrum3_001882; BiomolKI_000078; NCI60_041830; Bio1_001354; ghl.PD_Mitscher_leg0.1194; SPECTRUM200846; A828903; DivK1c_000798; 5-18-04-00574 (Beilstein Handbook Reference); 5-hydroxy-2-(4-hydroxyphenyl)-4-oxo-4H-chromen-7-olate; C.I. Natural Yellow 1; 461015-54-3; 4H-1-Benzopyran-4-one, 5,7-dihydroxy-2-(4-hydroxyphenyl)- (9CI); 5,7-dihydroxy-2-(4-hydroxyphenyl)chromone; SMP2_000338; BiomolKI2_000082; Prestwick0_000414; Tocris-1227; Lopac-A-3145; Bio1_000865; NSC83244; Versulin; Pelargidenon 1449; Bio1_000376; Spigenin; 5,7,4'-Trihydroxyflavone; ST056301; UCCF 031; SPBio_000416; Apigenine; C01477; CAS-520-36-5; BSPBio_003384 | C15H10O5 | 270.24 | C1=CC(=CC=C1C2=CC(=O)C3=C(C=C(C=C3O2)O)O)O |
| TCMBANKIN058321 | Norwogonin | 70U0WT21IB; AKOS027381297; ST50309217; 5,7,8-trihydroxy-2-phenyl-chromone; 2-Phenyl-5,7,8-trihydroxy-4H-1-benzopyran-4-one; 5,7,8-Trihydroxy-2-phenyl-4H-chromen-4-one; LS-69047; 4H-1-Benzopyran-4-one, 2-phenyl-5,7,8-trihydroxy-; UNII-70U0WT21IB; CHEBI:7642; 4H-1-Benzopyran-4-one, 2-phenyl-5,7,8-trihydroxy- (9CI); ZINC5934539; 4443/9/8; SCHEMBL760431; AC1NQYVA; MCULE-7196250903; 5,7,8-trihydroxy-2-phenylchromen-4-one; LMPK12111329; NSC128304; CTK4I8195; MFCD00016946; 4443-09-8; C-57553; ST5309217; AIDS016591; 5-18-04-00571 (Beilstein Handbook Reference); C10113; NCGC00385188-01!5,7,8-trihydroxy-2-phenylchromen-4-one; 5,7,8-Trihydroxyflavone; DTXSID20196171; norwogonin ; BRN 0272168; FLAVONE, 5,7,8-TRIHYDROXY-; 5,7,8-trihydroxy-2-phenyl-4-chromenone; MolPort-004-960-042; AK394875; CHEMBL485250; 5,7,8-trihydroxy-2-phenyl-chromen-4-one; norwogonin; AIDS-016591; NSC 128304; NSC-128304;nor-wogonin | C15H10O5 | 270.24 g/mol | C1=CC=C(C=C1)C2=CC(=O)C3=C(O2)C(=C(C=C3O)O)O |
| TCMBANKIN058704 | lupeol | AC-1371; AKOS015960466; SCHEMBL14067725; 4CN-0933; C08628; BC201808; Lup-20(29)-en-3.beta.-ol; NSC90487; ZINC04081455; D0RA6H; Lupeol; LMPR01060013; lupeol ; Monogynol B; .beta.-Viscol; NCI60_042005; lup-20(29)-en-3beta-ol; Lupenol | C30H50O | 426.7 g/mol | CC(=C)C1CCC2(C1C3CCC4C5(CCC(C(C5CCC4(C3(CC2)C)C)(C)C)O)C)C |
| TCMBANKIN058861 | ginsenoside rd;20-glucosylginsenosiderf;20-glucosylginsenosiderf | ginsenoside-rd; ginsenosiderd; A829210; 2-(hydroxymethyl)-6-[6-(hydroxymethyl)-2-[[17-[2-[6-(hydroxymethyl)-3,4,5-tris(oxidanyl)oxan-2-yl]oxy-6-methyl-hept-5-en-2-yl]-4,4,8,10,14-pentamethyl-3,12-bis(oxidanyl)-2,3,5,6,7,9,11,12,13,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-6-yl]oxy]-4,5-b; 2-[[2-[[3,12-dihydroxy-4,4,8,10,14-pentamethyl-17-[6-methyl-2-[[3,4,5-trihydroxy-6-(hydroxymethyl)-2-oxanyl]oxy]hept-5-en-2-yl]-2,3,5,6,7,9,11,12,13,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-6-yl]oxy]-4,5-dihydroxy-6-(hydroxymethyl)-3-oxanyl]oxy]-6;(2S,3R,4S,5S,6R)-2-[(2R,3R,4S,5S,6R)-2-[[(6S,14R)-3,12-dihydroxy-4,4,8,10,14-pentamethyl-17-[(2S)-6-methyl-2-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyhept-5-en-2-yl]-2,3,5,6,7,9,11,12,13,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-6-yl]oxy]-4,5-dihydroxy-6-(hydroxymethyl)oxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol; 20-glucosylginsenoside rf; AC1O3DDF;;20-glucosylginsenosiderf;20-glucosylginsenosiderf | C48H82O18 | 947.15 | CC(=CCCC(C)(C1CCC2(C1C(CC3C2(CC(C4C3(CCC(C4(C)C)O)C)OC5C(C(C(C(O5)CO)O)O)OC6C(C(C(C(O6)CO)O)O)O)C)O)C)OC7C(C(C(C(O7)CO)O)O)O)C |
| TCMBANKIN058867 | ginsenoside rb1 | Q-100470; A-D-glucopyranosyl)oxy]-12-hydroxydammar-24-en-3-yl ; GRb 1; MFCD00133367; ginsenosiderb1; Ginsenoside-Rb1 from Panax ginseng (Korean ginseng) root, triterpenoid saponin; beta-D-Glucopyranoside, (3-beta,12-beta)-20-((6-O-beta-D-glucopyranosyl-beta-D-glucopyranosyl)oxy)-12-hydroxydammar-24-en-3-yl 2-O-beta-D-glucopyranosyl-; N1620; NSC 310103; CHEBI:67989; Ginsenoside Rb1, primary pharmaceutical reference standard; C20713; Panax saponin E; 7413S0WMH6; Pseudoginsenoside D; 87700-07-0; A-Glucopyranosyl-(3; C54H92O23; A)-20-[(6-O-; 2-O-beta-Glucopyranosyl-(3beta,12beta)-20-((6-O-beta-D-glucopyranosyl-beta-D-glucopyranosyl)oxy)-12-hydroxydammar-24-en-3-yl-beta-D-glucopyranoside; Ginsenoside Rb1, European Pharmacopoeia (EP) Reference Standard; (3beta,12beta)-20-{[6-O-(beta-D-glucopyranosyl)-beta-D-glucopyranosyl]oxy}-12-hydroxydammar-24-en-3-yl 2-O-beta-D-glucopyranosyl-beta-D-glucopyranoside; 20(S)-ginsenoside Rb1; 2-O-; Ginsenoside Rb1 (saponin of panax ginseng); 52286-61-0; 12770-17-1; 393829-67-9; CS-3829; BIDD:ER0108; A,12; 2-O-beta-Glucopyranosyl-(3beta,12beta)-20-[(6-O-beta-D-glucopyranosyl-beta-D-glucopyranosyl)oxy]-12-hydroxydammar-24-en-3-yl beta-D-glucopyranoside; GZYPWOGIYAIIPV-JBDTYSNRSA-N; Ginsenoside-Rb1 from Panax ginseng (Korean ginseng) root; GS-Rb1; 41753-43-9; ginsenoside-rb1; ginsenoside r b1; 212055-66-8; UNII-7413S0WMH6; AB0016710; AKOS025311537; A-D-glucopyranoside; Ginsenoside rb1; MolPort-016-638-397; gensenoside Rb1; Gypenoside III; ginsenoside Rb1; CHEMBL501515; HY-N0039; Gynosaponin C; BDBM50317541; (3beta,12beta)-20-[(6-O-beta-D-glucopyranosyl-beta-D-glucopyranosyl)oxy]-12-hydroxydammar-24-en-3-yl 2-O-beta-D-glucopyranosyl-beta-D-glucopyranoside; Ambap41753-43-9; GSRb1; Ginsenoside-Rb1; 753G439; Sanchinoside E1; A-D-glucopyranosyl-; Panaxsaponin E; O899; ginsenoside-Rb1;gypenosideIII | C54H92O23 | 1109.3 g/mol | CC(=CCCC(C)(C1CCC2(C1C(CC3C2(CCC4C3(CCC(C4(C)C)OC5C(C(C(C(O5)CO)O)O)OC6C(C(C(C(O6)CO)O)O)O)C)C)O)C)OC7C(C(C(C(O7)COC8C(C(C(C(O8)CO)O)O)O)O)O)O)C |
| TCMBANKIN058915 | suberenon;suberenone | 7-Methoxy-6-(3-oxo-1-butenyl)coumarin; SUBERENONE; 7-Methoxy-6-(3-oxo-1-butenyl)-2H-1-benzopyran-2-one, 9CI; 7-methoxy-6-[(1E)-3-oxobut-1-en-1-yl]-2H-chromen-2-one; 7-methoxy-6-[(E)-3-oxobut-1-enyl]chromen-2-one; 7-methoxy-6-[-3-oxo-1-butenyl]-2h-1-benzopyran-2-one; 35897-95-1; AC1NT0MG | C14H12O4 | 244.24 g/mol | CC(=O)C=CC1=C(C=C2C(=C1)C=CC(=O)O2)OC |
| TCMBANKIN059614 | Amyrin | C30H50O | 426.72 | CC1(CCC2(CCC3(C(=CCC4C3(CCC5C4(CCC(C5(C)C)O)C)C)C2C1)C)C)C | |
| TCMBANKIN060679 | stigmasterol | C29H48O | 412.7 g/mol | CCC(C=CC(C)C1CCC2C1(CCC3C2CC=C4C3(CCC(C4)O)C)C)C(C)C | |
| TCMBANKIN061043 | MYS | C15H32 | 212.41 | CCCCCCCCCCCCCCC | |
| TCMBANKIN061071 | Ethylpalmitate | C18H36O2 | 284.5 g/mol | CCCCCCCCCCCCCCCC(=O)OCC | |
| TCMBANKIN061510 | tracheloside | C27H34O12 | 550.6 g/mol | COC1=C(C=C(C=C1)CC2COC(=O)C2(CC3=CC(=C(C=C3)OC4C(C(C(C(O4)CO)O)O)O)OC)O)OC | |
| TCMBANKIN061511 | arctigenin | AIDS002466; C10545; (3R,4R)-4-[(3,4-dimethoxyphenyl)methyl]-3-[(4-hydroxy-3-methoxy-phenyl)methyl]tetrahydrofuran-2-one; arctigenin ; Arctigenin; 41328-87-4; MLS002473154; NCGC00025291-01; MEGxp0_001799; HMS2198I14; Arctigenin, (+)-; (3S,4S)-4-[(3,4-dimethoxyphenyl)methyl]-3-[(4-hydroxy-3-methoxyphenyl)methyl]oxolan-2-one; 695QU32V04; SMR001397246; (3R,4R)-4-[(3,4-dimethoxyphenyl)methyl]-3-[(4-hydroxy-3-methoxyphenyl)methyl]oxolan-2-one; (3R,4R)-4-(3,4-dimethoxybenzyl)-3-(4-hydroxy-3-methoxy-benzyl)tetrahydrofuran-2-one; 7770-78-7; 26687-78-5; (3R,4R)-4-[(3,4-Dimethoxyphenyl)methyl]dihydro-3-[(4-hydroxy-3-methoxyphenyl)methyl]-2(3H)-furanone; AIDS-002466; ACon1_000416; Tocris-1777; (−)-Arctigenin; DTXSID50233381; UNII-2FD8L150E7 component NQWVSMVXKMHKTF-CVEARBPZSA-N; 2(3H)-Furanone, 4-((3,4-dimethoxyphenyl)methyl)dihydro-3-((4-hydroxy-3-methoxyphenyl)methyl)-, (3R-trans)-; (3R,4R)-4-[(3,4-dimethoxyphenyl)methyl]-3-[(4-hydroxy-3-methoxyphenyl)methyl]-2-tetrahydrofuranone; (-)-Arctigenin; UNII-695QU32V04; 2(3H)-Furanone, 4-((3,4-dimethoxyphenyl)methyl)dihydro-3-((4-hydroxy-3-methoxyphenyl)methyl)-, (3S-trans)-; A1854_SIGMA; Arctigenen; 84413-77-4; Arctigenin, trans-(+)-; (3R,4R)-4-[(3,4-dimethoxyphenyl)methyl]-3-[(4-hydroxy-3-methoxy-phenyl)methyl]oxolan-2-one; (+)-Arctigenin; 2(3H)-Furanone, 4-((3,4-dimethoxyphenyl)methyl)dihydro-3-((4-hydroxy-3-methoxyphenyl)methyl)-, (3S,4S)-; ZINC899931; 2(3H)-Furanone, 4-((3,4-dimethoxyphenyl)methyl)dihydro-3-((4-hydroxy-3-methoxyphenyl)methyl)-, (3R,4R)-; CHEMBL369142; (-)-arctigenin | C21H24O6 | 372.4 g/mol | COC1=C(C=C(C=C1)CC2COC(=O)C2CC3=CC(=C(C=C3)O)OC)OC |
| TCMBANKIN061576 | subaphylline | Subaphylline; (2E)-N-(4-aminobutyl)-3-(4-hydroxy-3-methoxyphenyl)prop-2-enimidic acid; AX8235677; N-(4-aminobutyl)-3-(4-hydroxy-3-methoxyphenyl)prop-2-enimidic acid; TC-158316; SFUVCMKSYKHYLD-FNORWQNLSA-N; KB-258187; 2-Propenamide, N-(4-aminobutyl)-3-(4-hydroxy-3-methoxyphenyl)- (9CI); AK104138; 501-13-3; MFCD01736565; NSC602818; 4-Oxy-3-methoxycinnamylputrescine; AKOS016006183; 2-Propenamide, N-(4-aminobutyl)-3-(4-hydroxy-3-methoxyphenyl)-; AC1NQZ3Q; (E)-N-(4-aminobutyl)-3-(4-hydroxy-3-methoxyphenyl)prop-2-enamide; CHEBI:9299; LS-53858; (2E)-N-(4-AMINOBUTYL)-3-(4-HYDROXY-3-METHOXYPHENYL)PROP-2-ENAMIDE; N-Feruloylputrescine; (E)-N-(4-aminobutyl)-3-(4-hydroxy-3-methoxy-phenyl)prop-2-enamide; (E)-N-(4-aminobutyl)-3-(4-hydroxy-3-methoxyphenyl)acrylamide; Subaphyllin; N-(4-Aminobutyl)-3-(4-hydroxy-3-methoxyphenyl)acrylamide; Feruloylputrescine; ZINC1531868; MolPort-044-723-792; trans-N-Feruloylputrescine; 6850AB; C10497; 91000-11-2; AK677578; CINNAMAMIDE, N-(4-AMINOBUTYL)-4-HYDROXY-3-METHOXY-; AJ-26737; NSC-602818; (2E)-N-(4-Aminobutyl)-3-(4-hydroxy-3-methoxyphenyl)-2-propenamide #; N-(E)-Feruloylputrescine; MolPort-023-333-229; N-(4-Aminobutyl)-4-hydroxy-3-methoxycinnamamide; subaphyllin | C14H20N2O3 | 264.32 g/mol | COC1=C(C=CC(=C1)C=CC(=O)NCCCCN)O |
| TCMBANKIN061627 | matairesinol | 41328-88-5; AIDS030806; (-)-Matairesinol; Matairesinol; 3R,4R-Bis((4-hydroxy-3-methoxyphenyl)methyl)dihydro-2(3H)-furanone; AIDS-030806; (3R,4R)-3,4-bis[(4-hydroxy-3-methoxy-phenyl)methyl]tetrahydrofuran-2-one; ARTIGENIN CONGENER; (3R,4R)-3,4-bis(4-hydroxy-3-methoxy-benzyl)tetrahydrofuran-2-one; 580-72-3; DIBENZYLBUTYROLACTONE LIGNANOLIDE; (3R,4R)-3,4-bis[(4-hydroxy-3-methoxyphenyl)methyl]oxolan-2-one; 40043_FLUKA; MEGxp0_001689; (3R,4R)-3,4-bis[(4-hydroxy-3-methoxy-phenyl)methyl]oxolan-2-one; Arbo 5; C10682; (3R,4R)-3,4-bis[(4-hydroxy-3-methoxyphenyl)methyl]-2-tetrahydrofuranone; (alphaR,betaR)-alpha,beta-Bis(4-hydroxy-3-methoxybenzyl)butyrolactone; ACon1_001075; 2(3H)-Furanone, dihydro-3,4-bis((4-hydroxy-3-methoxyphenyl)methyl)-, (3R-trans)-;(- )-matairesinol;MAX | C20H22O6 | 358.4 g/mol | COC1=C(C=CC(=C1)CC2COC(=O)C2CC3=CC(=C(C=C3)O)OC)O |
| TCMBANKIN061902 | dambonitol | dambonite | C8H16O6 | 208.21 | COC1C(C(C(C(C1O)OC)O)O)O |
植物对应的疾病
| 疾病ID | 病名 | 疾病类型 | MeSH | 参考文献 |
|---|
植物对应的靶点
| 靶点ID | 基因名 | 基因别名 | 描述 | 染色体位置 | Map_Location | 基因类型 |
|---|
滇ICP备16009434号-1 |
Dai SX Lab